InvestorsHub Logo
Followers 229
Posts 21457
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Tuesday, 12/21/2021 7:57:55 AM

Tuesday, December 21, 2021 7:57:55 AM

Post# of 2847
Sonnet BioTherapeutics Holdings (SONN) Gets a Buy Rating from H.C. Wainwright
December 21 2021 - 02:09AM
TipRanks
Print
Share On Facebook
H.C. Wainwright analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Monday at $0.47, close to its 52-week low of $0.43. According to TipRanks.com, King is a 5-star analyst with an average return of 20.2% and a 52.2% success rate. King covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Werewolf Therapeutics, and Compass Therapeutics. Sonnet BioTherapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $3.17, a 574.5% upside from current levels.
https://www.tipranks.com/news/blurbs/sonnet-biotherapeutics-holdings-sonn-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SONN News